Plasma Fractionation Market Size is valued at USD 4.2 Bn in 2023 and is predicted to reach USD 8.9 Bn by the year 2031 at a 10.1 % CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
- The demand for plasma-derived therapies has been increasing due to the rising prevalence of immune deficiencies, respiratory infections, including other disorders.
- Increased awareness and improved diagnostic services have led to more accurate identification and diagnosis of rare diseases, which is resulting in driving industry growth.
- North America ruled the market and accounted for a revenue share of global revenue in 2023.
- One of the major concerns restraining industry growth is stringent regulatory requirements and complex approval processes for plasma-derived products.
Plasma fractionation is an important technique in medicine and biotechnology, particularly in manufacturing numerous medicinal compounds generated from human blood plasma. It entails separating and isolating various components found in blood plasma to produce specialized medicinal products. The increased incidence of senior people around the world, who are more prone to rare conditions that necessitate the use of blood derivatives, is a primary driver of the market's rise. Furthermore, the rising use of immunoglobulins and alpha-1-antitrypsin in numerous departments of medicine worldwide is expected to fuel market expansion. Moreover, the growth of this market is influenced by the increase in blood-collecting facilities around the world.
However, lockdowns, social distancing measures, and fears of viral transmission hampered plasma collection from willing donors during the COVID-19 pandemic. Despite the devastating impact of the current coronavirus pandemic on some enterprises, the worldwide sector has risen tremendously in recent years. As the COVID-19 pandemic peaked, more people were negatively affected by the viral infection, necessitating the use of plasma as a treatment.
Competitive Landscape
Some Major Key Players In The Plasma Fractionation Market:
- CSL (Australia)
- Takeda Pharmaceutical Company Limited (Japan)
- Grifols, S.A. (Spain)
- Octapharma AG (Switzerland)
- Kedrion S.P.A (Italy)
- LFB (France)
- ADMA Biologics (US)
- Sanquin (Netherlands)
- China Biologic Products Holdings Inc. (China)
- GC Pharma (Korea)
- Hualan Bioengineering Co., Ltd. (China)
- Japan Blood Products Organization (Japan)
- Emergent BioSolutions (US)
- Shanghai Raas Blood Products Co., Ltd. (China)
- Intas Pharmaceuticals Ltd. (India)
- Bharat Serum Vaccines Limited (India)
- SK Plasma (Korea)
- Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)
- Kamada (Israel)
- Centurion Pharma (Istanbul)
- Prothya Biosolutions (Netherlands)
- PlasmaGen BioSciences Pvt. Ltd. (India)
- Virchow Biotech Private Limited (India)
- Fusion Healthcare (India)
- Hemarus Therapeutics Limited (India)
- Others
Market Segmentation:
The Plasma Fractionation Market consists of Product, application, and end-user segments. As per the product, the market is segmented as immune-globulins, coagulation factor concentrates, albumin, protease inhibitors, and other plasma products. The immune-globulins segment includes intravenous immune globulins, subcutaneous immune globulins, and other immune globulins. By coagulation factor concentrates, the market is segmented into Von Willebrand factor, Factor VIII, Factor IX, prothrombin complex concentrate, fibrinogen concentrates, Factor XIII, and others. The applications segment includes neurology, immunology, haematology, critical care, pulmonology, hemato-oncology, rheumatology, and others. The end-user segment includes hospitals & clinics, clinical research laboratories, and academic institutes.
Based On Product, The Immune-Globulins Segment Is Accounted As A Major Contributor In The Plasma Fractionation Market.
The immune-globulins category is expected to hold a major share in the global Plasma Fractionation Market in 2022. The enormous demand for IVIG treatments for primary and secondary immunodeficiency illnesses explains the company's supremacy. The rising prevalence of such diseases, combined with advancements in treatment, has resulted in a surge in demand for intravenous immunoglobulin. Significant product launches by prominent market players also contribute to the growth of the coagulation factors category. Immunoglobulin therapy is increasingly used to treat diseases other than immunodeficiency disorders. It is used to treat autoimmune diseases, neurological disorders, and inflammatory ailments, which increases its market potential.
The Hospitals & Clinics Segment Witnessed Growth At A Rapid Rate.
The hospitals & clinics segment is probable to grow at a rapid rate in the global Plasma Fractionation Market. The segment is expected to rise significantly due to increased off-label use of plasma fractionation products in hospitals to treat a number of disorders, improved infrastructure, and a rise in healthcare services provided by hospitals. Furthermore, plasma fractionation products are in high demand for complicated illnesses that can be addressed in modern therapeutic settings.
In The Region, The Asia Pacific Plasma Fractionation Market Holds A Significant Revenue Share.
The Asia Pacific Plasma Fractionation Market is expected to register the maximum market share in terms of revenue in the near future. This is due to growing knowledge of the multiple benefits of plasma, as well as an increase in the prevalence of respiratory illnesses. Furthermore, the presence of important players, an increase in the count of plasma collection facilities, an increase in immunoglobulin consumption, and the capacity to deliver plasma due to plasma collection and distribution viability all contribute to the regional market's growth.
As a result of favourable government regulations, increased public and private funding for research and development, increased use of immunoglobulins, rising prevalence of target diseases with an ageing population with blood-related diseases, and rising plasma-based treatment adoption, the plasma fractionation market is expanding.
Recent Developments:
- In March 2023, Takeda made an investment of 100 billion JPY in the establishment of a novel manufacturing facility in Japan, specifically dedicated to the production of plasma-derived medicines. The investment made by Takeda exemplified the company's dedication to prioritising patients and fulfilling its obligations in relation to its patient-centric, people-oriented, and environmentally conscious objectives. This approach was supported by the utilisation of data and digital technologies.
- In Dec 2022, CSL has recently inaugurated its Plasma Fractionation Facility in Victoria, Australia, which represents a significant milestone in the country's plasma manufacturing sector. With a staggering investment of $900 Bn, this state-of-the-art facility stands as the largest of its type in the Southern Hemisphere. The aforementioned statement pertains to a capital investment programme of over $2 billion that CSL is presently implementing in Australia.
Plasma Fractionation Market Report Scope:
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 4.2Bn |
|
Revenue Forecast In 2031 |
USD 8.9 Bn |
|
Growth Rate CAGR |
CAGR of 10.1 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, application, and end-user |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
CSL (Australia), Takeda Pharmaceutical company limited (Japan), Grifols, S.A. (Spain), Octapharma AG (Switzerland), Kedrion S.P.A (Italy), LFB (France), ADMA Biologics (US), Sanquin (Netherlands), China Biologic Products Holdings Inc. (China), GC Pharma (Korea), Hualan Bioengineering Co., Ltd. (China), Japan Blood Products Organization (Japan), Emergent BioSolutions (US), Shanghai Raas Blood Products Co., Ltd. (China), Intas Pharmaceuticals Ltd. (India), Bharat Serum Vaccines Limited (India), SK Plasma (Korea), Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China), Kamada (Israel), Centurion Pharma (Istanbul), Prothya Biosolutions (Netherlands), PlasmaGen BioSciences Pvt. Ltd. (India), Virchow Biotech Private Limited (India), Fusion Healthcare (India), and Hemarus Therapeutics Limited (India) |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
